Ostman-Smith et al. Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy
measure all ECGs blindly for the current study as original ECGs from the earlier decades were no longer accessible, thus the ECG-measures originally entered into the registry had to be used for the calculation of ECG risk-scores. From 2000 ECGs were measured prospectively as patients entered into the registry, and virtually all ECGs were digitally recorded allowing automatic calculation of QRS-duration, QTc, voltages and ST-T-wave deviations by the ECG-machine to be utilized, so bias does not arise and reproducibility is excellent. Original ultrasound measurements, M-mode, and where available, 2-D ultrasound measurements were re-measured where available (IÖS and EF), or otherwise reports in hospital notes were accepted. Detroit Z-scores for maximal wall thickness have been calculated using the Cardio Z app, 6 and septal thickness related to upper limit of normal for age (SEPPER) according to the published formula.
1 However we found that the choice of Zscore had very great influence on values, and whereas we got a normal distribution of Z-score values within ±2 on our normal patients with the Detroit Z-score, we obtained very much higher Z-score values with the Kampmann Z-score 7 , with 19% of normal patients having Zscore values >2. Accordingly, only Detroit Z-score values are used. An LVOT gradient >20 mm Hg at rest was considered significant obstruction (LVOTO).
8 Presence of obvious systolic anterior movement of mitral-valve apparatus (SAM) plus a systolic murmur was judged evidence of LVOTO in era before Doppler measurements available. 24h-Holter ECGrecordings were not available in the 1970-ies so Holter data is available only for later patients. Exercise-testing on a bicycle ergometer has been available from the outset, but blood pressure response was not always recorded. Hospital records were scrutinized for information about syncope and family history of sudden death. Latest ultrasound-and ECG measures recorded were retrieved from the hospital records, even for those patients that had entered adult cardiology follow-up, and in the majority last follow-up measurements are obtained within one-two years of the end-point. Medical treatments given, and interventional procedures have been documented. 101 patients (62.4%) received beta-blocker therapy (mostly propranolol or metoprolol, and only 2% received atenolol), 14 (8.6%) had calcium-blocker therapy, and 7 (4.3%) amiodarone. 39 (24.0%) patients received a combination of disopyramide and highdose beta-blocker. All patients receiving high-dose propranolol or metoprolol received slowrelease preparations twice daily. Beta-blocker doses used were converted to propranolol equivalents using the conversion propranolol 80 mg = metoprolol 100mg 9 = bisoprolol 5 mg = atenolol 50 mg.
Causes of death All Swedish nationals have a unique personal identification number, and if patient was alive or dead was last ascertained on October 6th 2016. Where causes of death were not recorded in hospital notes, they were obtained from death certificates from National Board of Health and Welfare. Apart from the 39 classed as SD/CA-group, there were 17 additional cardiac deaths. No patient was lost to follow-up.
Statistics Statistical analyses were carried out using Statgraphics Centurion XVI, GraphPad Prism v. 6.02, and IBM SPSS Statistics v. 22 software. Categorical data were compared with two-tailed Fisher´s exact test, and continuous variables with Mann-Witney U-test as the majority of parameters were not normally distributed. Survival was analysed by Kaplan-Meier survival curves compared with log-rank test. Comparisons of relative risk for various risk factors were made both for previously published suggested cut-off values, and where these performed poorly, by analysis of the frequency distribution of the those parameters comparing survivors with individuals in the SCD-group compared to survivors. For the uni-and multivariate analysis of risk-factors with Cox proportional hazards method on the other hand all patients with ECG-and ultrasound data (n=140) were included, even those who had died another type of cardiac death, but sudden death was still used as primary end-point, in order to study how specific various risk factors were for arrhythmia-associated death. Parameters were selected for multivariate analysis if univariate p-values were ≤0.20. The number of variables was restricted to six at a time in order to have adequate statistical power, based on statistician advice, and were analyzed with backward selection. O'Mahony et al, 2014 10 have suggested that one risk-factor per 10 end-points would be appropriate for risk-factor assessment in adult HCM, but they had an annual event rate of 0.81% whereas we had an event rate of 1.7% giving us substantially greater statistical power, and explaining divergence of statistical advice. Those risk-factors not significant in the six-factor analysis were removed and others entered until all had been tested. Only one ECG-parameter and one wall-thickness measure was included in each group-analysis, and bivariate analysis of two ECG-measures or two wallthickness measures together was used to determine which of the two were the most powerful predictors, as they would have some linkage to each other. The risk-factors included in the AHA risk assessment-model were also re-tested one by one in the final multivariate models, even if they had significance values >0.2 on univariate analysis, and finally the last model was tested with only three or four risk-factors included in the model to obtain the most accurate parameters for the regression. The AHA risk-factors was included as recommended in the 2011 AHA guidelines, 11 with pathological blood pressure reaction not counted as significant risk factors unless other risk factors were present; however nsVT if present was counted as risk factor considering the patients young age. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 accf/aha guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Developed in collaboration with the american association for thoracic surgery, american society of echocardiography, american society of nuclear cardiology, heart failure society of america, heart rhythm society, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2011; 58:e212-260 Supplemental 
